SMA II

Cerebral Palsy

The subjects will be treated with paracetamol in therapeutic doses, 15mg/kg/dose every six hour, with a maximum dosage of 1 g x 4 per day, for three consecutive days.

Paracetamol 120Mg/5mL Oral Suspension

Copenhagen Neuromuscular Center

Paracetamol Study in Patients With Low Muscle Mass

Pharmacokinetics and Safety of Treatment With Paracetamol in Children and Adults With Spinal Muscular Atrophy and Cerebral Palsy

- Clearance (total, glucuronidation, sulphation, CYP2E1 oxidation and unchanged) of paracetamol in patients with SMA, CP and ICU-admitted patients with either SMA or CP

- Clearance (total paracetamol) of paracetamol in patients with SMA, CP and ICU-admitted patients with either SMA or CP

- Clearance (glucuronidation) of paracetamol in patients with SMA, CP and ICU-admitted patients with either SMA or CP

- Clearance (sulphation) of paracetamol in patients with SMA, CP and ICU-admitted patients with either SMA or CP

- Clearance (CYP2E1 oxidation) of paracetamol in patients with SMA, CP and ICU-admitted patients with either SMA or CP

- Clearance (unchanged paracetamol) of paracetamol in patients with SMA, CP and ICU-admitted patients with either SMA or CP

- Volume of distribution of paracetamol in patients with SMA, CP and ICU-admitted patients with SMA or CP, in comparison with healthy controls.

- Liver function tests in patients with SMA, CP and ICU-admitted patients with SMA or CP.: ALT, AST, LDH, Alkaline Phosphatase, Bilirubin (U/L)

- Concentration-time data on plasma paracetamol, paracetamol-sulphate, paracetamol-glucuronide, paracetamol-cysteine and paracetamol-mercapturate (oxidative metabolites), plasma-glutathione and liver biomarkers (ALAT, PP, bilirubin, MicroRNA-122 (miR-122)).

Mette Cathrine Oerngreen

Principal Investigator

Elsass Foundation

Physical exercises were performed during HD sessions, at second hour of HD, three times per week for 3 months (36 sessions). The patients remained seated while performing the exercises that were performed in both lower limbs. Ankle-cuffs and elastic bands (Theraband®, Akron-OH, USA) were used for performed the exercises. The physical exercises consisted of four different exercises and they were administered by a physical therapist following the adapted protocol.

Chronic Kidney Disease

Hypertension

Diabetes

Physical exercises were performed during HD sessions, at second hour of HD, three times per week for 3 months. The first exercise was knee extension from 90° to 0°. The patient remained in the 0° position for 5 seconds (an isometric contraction) and then returned to the starting position (90º). 2) The second exercise consisted of a triple flexion followed by extension of the lower limbs. The patient flexed the thigh, knee and ankle (elastic band placed at the level of the metacarpals) followed by a double extension of the thigh and knee. 3) In a co-isometric contraction, the patient performed a leg extension against the ankle-cuff resistance (located under the distal third of the leg at the level of the malleolus) for 10 seconds. 4) The patient performed a unilateral hip joint flexion of the lower limb with the knee extended by rising to their functional limit.

physical exercises

Denise Mafra

Effects of Physical Activities on the Expression of Nrf2 and Nf-kb Hemodialysis Patients

Effects of a Program of Strength Physical Activities on the Expression of Nrf2 and Nf-kb Hemodialysis Patients

cytokines plasma levels like interleukin-6, TNF-alpha evaluated by ELISA methods

Professor

Universidade Federal Fluminense

non-smoker oral placebo
non-smoker oral placebo: Participants oral placebo last 2 weeks.

IVnon-smoker + Placebo

non-smoker oral melatonin
non-smoker oral melatonin: Participants oral melatonin 3 mg/day last 2 weeks.

IIInon-smoker + Melatonin

smoker oral placebo
smoker oral placebo: Participants oral placebo last 2 weeks.

IIsmoker + Placebo

smoker oral melatonin
smoker oral melatonin: Participants oral melatonin 3 mg/day last 2 weeks.

Ismoker + Melatonin

Total

Sex: Female, Male

IV Non-smoker + Placebo

III Non-smoker + Melatonin

II Smoker + Placebo

I Smoker + Melatonin

Smoke-induced Vascular Injury and Melatonin's Effect in This Process Assessed by the Concentration of Fbg.

Smoke-induced Vascular Injury and Melatonin's Effect in This Process Assessed by the Concentration of Glu.

Smoke-induced Vascular Injury and Melatonin's Effect in This Process Assessed by the Concentration of FFA.

Smoke-induced Vascular Injury and Melatonin's Effect in This Process Assessed by the Concentration of TC.

Smoke-induced Vascular Injury and Melatonin's Effect in This Process Assessed by the Concentration of TG.

Smoke-induced Vascular Injury and Melatonin's Effect in This Process Assessed by the Concentration of LDL-C.

Overall Study

Prof. Changwei Liu. Director of vascular surgery.

Non-smoker + Placebo

Non-smoker + Melatonin

Smoker + Placebo

Smoker + Melatonin

Smoking

Vascular System Injuries

non-smoker oral placebo

Participants oral melatonin 3 mg/day last 2 weeks.

non-smoker oral melatonin

smoker oral placebo

smoker oral melatonin

PekingUMCH

Melatonin in Smoke-induced Vascular Injury

The Protective Effect of Melatonin on Smoke-induced Vascular Injury in Human

The cycle of the experiment is long, and it is a part of the experiment.

Peking Union Medical College Hospital

18-35 yr old healthy subjects with wild type genotype for NQO1.

18-35 yr old healthy subjects who are homozygotic for minor allele of NQO1 Pro187Ser polymorphism

quinone/upala

Paracetamol Study in Patients With Low Muscle Mass

Effects of Physical Activities on the Expression of Nrf2 and Nf-kb Hemodialysis Patients

Melatonin in Smoke-induced Vascular Injury

Lung Mucus Hypersecretion and NQO1

Najkompletnija baza ljekovitog bilja potpomognuta znanošću